More about Nontuberculous Mycobacterial Lung Disease
The 2020 ATS/ERS/ESCMID/IDSA guideline counts more than 190 species and subspecies. They live in soil and water, and most people who breathe them in never get sick. NORD says most evidence shows the infection is picked up from the environment rather than passed between people.
Keep reading about Nontuberculous Mycobacterial Lung Disease
Mycobacterium avium complex, the group that includes M. avium, M. intracellulare and M. chimaera, accounts for about half of all NTM infections, according to NORD. Other species include M. kansasii and M. abscessus, which grows fast and is harder to treat; NORD gives treatment success rates of 41-46% for M. abscessus.
The germs take hold most easily in airways that cannot clear mucus well. NORD describes mucus in damaged airways as a home where NTM can hide from the immune system. Over years, repeated infection can widen and scar the airways (bronchiectasis) or hollow out cavities in the upper lungs, and untreated cavitary disease can lead to scarring and breathing failure.
The 2020 guideline sets 3 requirements before NTM lung disease is diagnosed. The first is lung or body-wide symptoms. The second is a chest X-ray or CT scan showing nodules, cavities or bronchiectasis with small nodules, after other diagnoses have been ruled out. The third is the same NTM species grown from at least 2 separate sputum samples or from 1 bronchoscopy wash. A lung biopsy showing mycobacterial changes, plus a positive NTM culture, also counts. A single positive sputum culture is not enough, because NTM from the environment can end up in a sample. MAC grows slowly, taking 2 to 4 weeks on solid culture media, so results take time (NORD).
Not everyone needs antibiotics right away, and NORD notes that some slow infections are watched with regular check-ups. For people who meet the criteria, the guideline suggests starting treatment rather than waiting, especially when a sputum smear is positive or the lungs have cavities. The guideline says that choice should weigh the infecting species and the person's own priorities.
For MAC that is still sensitive to macrolide antibiotics, the guideline recommends a regimen of at least 3 drugs that includes a macrolide. Its preferred regimen is azithromycin (or clarithromycin), a rifamycin such as rifampin (or rifabutin) and ethambutol. The guideline prefers azithromycin because it is better tolerated, has fewer drug interactions and is taken once a day.
For the milder nodular bronchiectatic form, the guideline suggests taking the 3 drugs 3 times a week. For cavitary or advanced disease it suggests daily doses, with intravenous amikacin or streptomycin added at the start. Treatment continues for at least 12 months after sputum cultures turn negative.
When cultures are still positive after 6 months, the guideline recommends adding amikacin liposome inhalation suspension, sold as Arikayce. For newly diagnosed MAC, the 2020 guideline suggested not using inhaled amikacin at the start, a recommendation written before Insmed's ENCORE trial reported results in 2026.
These long courses are hard to stay on, and NORD lists stomach upset, hearing loss and liver problems among the side effects. NORD also describes airway clearance (chest physical therapy, nebulized salt water, postural drainage and oscillation vests), surgery for some localized disease, and steps against reinfection. Those steps include setting water heaters to at least 130°F, using bathroom and kitchen fans, avoiding hot tubs and wetting potting soil before handling it.
What are the symptoms of Nontuberculous Mycobacterial Lung Disease?
These are common symptoms of Nontuberculous Mycobacterial Lung Disease, and how strong they are varies from person to person.
- A cough that lasts for weeks or months, often bringing up mucus (sputum)
- Tiredness (fatigue)
- Shortness of breath (dyspnea)
- Fever, night sweats and loss of appetite
- Weight loss without trying
- Coughing up blood (hemoptysis) or chest pain in some people
- Chest infections that keep coming back and slowly damage the airways
Who gets Nontuberculous Mycobacterial Lung Disease?
NTM lung disease is much more common in older adults and somewhat more common in women. In the 2020 claims study, the rate at 65 or older was about 4 times the overall rate. Women also had a higher rate than the population as a whole, 16.78 against 11.70 per 100,000 in 2015.
NORD describes 2 common patterns. The nodular bronchiectatic form mostly affects thin, middle-aged or older women of white or Asian descent, often with no history of smoking or lung disease. Some of them have a sunken chest (pectus excavatum), a curved spine (scoliosis), mitral valve prolapse or a single change in the cystic fibrosis gene. The cavitary form, which leaves holes in the upper lungs, is more common in people who smoke or have COPD.
Other lung conditions raise the risk, including bronchiectasis, COPD, cystic fibrosis, primary ciliary dyskinesia and alpha-1 antitrypsin deficiency, according to NORD. Rare immune defects and medicines that weaken the immune system, such as TNF blockers, also raise it. People with no earlier lung disease can be affected too.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Nontuberculous Mycobacterial Lung Disease?
There is currently 1 FDA-approved medication for Nontuberculous Mycobacterial Lung Disease.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Nontuberculous Mycobacterial Lung Disease treatment
Charity funds and drugmaker programs for Nontuberculous Mycobacterial Lung Disease, checked at the source.
No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.
Every program and fund for Nontuberculous Mycobacterial Lung Disease, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
How Nontuberculous Mycobacterial Lung Disease is diagnosed
NTM lung disease is an infection picked up from the environment, not an inherited condition. NORD notes that rare inherited immune defects, such as interferon gamma receptor, STAT1 or GATA2 deficiency, raise the risk. Some people with the nodular form also carry a single change in the cystic fibrosis gene.
Trusted Nontuberculous Mycobacterial Lung Disease resources
Reputable organizations and medical references for learning more about Nontuberculous Mycobacterial Lung Disease, including disease registries, foundation resources, and clinical guidelines.
- National Organization for Rare Disorders (NORD) - Nontuberculous Mycobacterial Lung Disease (updated September 12, 2024)
- NIH Genetic and Rare Diseases Information Center (GARD) - Pulmonary non-tuberculous mycobacterial infection (GARD:0012829)
- Daley et al., Clin Infect Dis 2020 - Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
- Winthrop et al., Ann Am Thorac Soc 2020 - Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015
- Strollo et al., Ann Am Thorac Soc 2015 - The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States
- Arikayce (amikacin liposome inhalation suspension) prescribing information (DailyMed, revised June 2026)
- FDA - NDA 207356 accelerated approval and LPAD pathway approval letter for Arikayce (September 28, 2018)
- Insmed - FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 (September 21, 2026)
- Insmed - Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease (March 23, 2026)
- Insmed - Third-Quarter 2026 Financial Results and Business Update (October 29, 2026)
- ClinicalTrials.gov: BOOST, therapeutic BCG in MAC lung disease (NCT07094711)
- ClinicalTrials.gov: CLAZI, clarithromycin versus azithromycin in MAC lung infections (NCT03236987)
- ClinicalTrials.gov: REBOUND, epetraborole in Mycobacterium abscessus lung disease (NCT07301320)
- Bronchiectasis and NTM Association (COPD Foundation) - Evolution to Association